King & Wood Mallesons has advised Pfizer Inc on its $295 million joint venture with Zhejiang Hisun Pharmaceutical Co Ltd, represented by Jun He. This is Pfizer's largest joint venture in China.
Hisun Pfizer Pharmaceutical Co Ltd is expected to manufacture and sell off-patent pharmaceutical products, including generic drugs, in China and the global market as well. The project is one of the first generic medicine projects that China is setting up jointly with multinationals, and also one of the largest pharmaceutical joint venture projects in the wealthy province of Zhejiang.
A team from King & Wood Mallesons’ China offices, led by partners Wang Kaiding, Zhang Xiaolian, Ning Xuanfeng and Xiao Jin, provided Pfizer legal services from deal structure to due diligence, and also antitrust review.
Liu Zhen is China senior journalist at ALB. Follow us on Twitter: @ALB_Magazine.
Other related stories are:
